When times got tough, the biopharma industry hit the Zoom button and kept things moving at a multibillion-dollar clip
Don’t ever underestimate biopharma’s ability to grab ahold of an opportunity, even if they can’t close a deal with a handshake.
While retail and other industries struggle to survive a vicious downturn brought on by the pandemic, biopharma continues to make fresh gains — or stay on an elevated track — on most dealmaking fronts. And this new set of charts from DealForma chief Chris Dokomajilar underscores the heightened level of activity this past spring.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.